These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Juvenile myelomonocytic leukemia with less aggressive clinical course and KRAS mutation. Imamura M; Imai C; Takachi T; Nemoto T; Tanaka A; Uchiyama M Pediatr Blood Cancer; 2008 Oct; 51(4):569. PubMed ID: 18561174 [No Abstract] [Full Text] [Related]
4. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network. Caye A; Strullu M; Guidez F; Cassinat B; Gazal S; Fenneteau O; Lainey E; Nouri K; Nakhaei-Rad S; Dvorsky R; Lachenaud J; Pereira S; Vivent J; Verger E; Vidaud D; Galambrun C; Picard C; Petit A; Contet A; Poirée M; Sirvent N; Méchinaud F; Adjaoud D; Paillard C; Nelken B; Reguerre Y; Bertrand Y; Häussinger D; Dalle JH; Ahmadian MR; Baruchel A; Chomienne C; Cavé H Nat Genet; 2015 Nov; 47(11):1334-40. PubMed ID: 26457648 [TBL] [Abstract][Full Text] [Related]
5. Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia. Yoshida N; Yagasaki H; Xu Y; Matsuda K; Yoshimi A; Takahashi Y; Hama A; Nishio N; Muramatsu H; Watanabe N; Matsumoto K; Kato K; Ueyama J; Inada H; Goto H; Yabe M; Kudo K; Mimaya J; Kikuchi A; Manabe A; Koike K; Kojima S Pediatr Res; 2009 Mar; 65(3):334-40. PubMed ID: 19047918 [TBL] [Abstract][Full Text] [Related]
6. Mutation analysis of the BRAF oncogene in juvenile myelomonocytic leukemia. de Vries AC; Stam RW; Kratz CP; Zenker M; Niemeyer CM; van den Heuvel-Eibrink MM; Haematologica; 2007 Nov; 92(11):1574-5. PubMed ID: 18024410 [TBL] [Abstract][Full Text] [Related]
7. How a rare pediatric neoplasia can give important insights into biological concepts: a perspective on juvenile myelomonocytic leukemia. Flotho C; Kratz CP; Niemeyer CM Haematologica; 2007 Nov; 92(11):1441-6. PubMed ID: 18024390 [No Abstract] [Full Text] [Related]
8. Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia. Koike K; Matsuda K Br J Haematol; 2008 May; 141(5):567-75. PubMed ID: 18422786 [TBL] [Abstract][Full Text] [Related]
9. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia. Pérez B; Kosmider O; Cassinat B; Renneville A; Lachenaud J; Kaltenbach S; Bertrand Y; Baruchel A; Chomienne C; Fontenay M; Preudhomme C; Cavé H Br J Haematol; 2010 Dec; 151(5):460-8. PubMed ID: 20955399 [TBL] [Abstract][Full Text] [Related]
17. Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations. Sugimoto Y; Muramatsu H; Makishima H; Prince C; Jankowska AM; Yoshida N; Xu Y; Nishio N; Hama A; Yagasaki H; Takahashi Y; Kato K; Manabe A; Kojima S; Maciejewski JP Br J Haematol; 2010 Jul; 150(1):83-7. PubMed ID: 20408841 [TBL] [Abstract][Full Text] [Related]
18. Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations. Yoshida N; Doisaki S; Kojima S Paediatr Drugs; 2012 Jun; 14(3):157-63. PubMed ID: 22480363 [TBL] [Abstract][Full Text] [Related]
19. Gene mutations in the Ras pathway and the prognostic implication in Korean patients with juvenile myelomonocytic leukemia. Park HD; Lee SH; Sung KW; Koo HH; Jung NG; Cho B; Kim HK; Park IA; Lee KO; Ki CS; Kim SH; Yoo KH; Kim HJ Ann Hematol; 2012 Apr; 91(4):511-7. PubMed ID: 21901340 [TBL] [Abstract][Full Text] [Related]
20. Somatic mosaicism for oncogenic NRAS mutations in juvenile myelomonocytic leukemia. Doisaki S; Muramatsu H; Shimada A; Takahashi Y; Mori-Ezaki M; Sato M; Kawaguchi H; Kinoshita A; Sotomatsu M; Hayashi Y; Furukawa-Hibi Y; Yamada K; Hoshino H; Kiyoi H; Yoshida N; Sakaguchi H; Narita A; Wang X; Ismael O; Xu Y; Nishio N; Tanaka M; Hama A; Koike K; Kojima S Blood; 2012 Aug; 120(7):1485-8. PubMed ID: 22753870 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]